Reviewer's report

Title: Tiotropium's cost-effectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions.

Version: 1 Date: 20 November 2009

Reviewer: Lotte Steuten

Reviewer's report:

This is a very well performed economic evaluation and especially interesting given the history of reimbursement decisions in favour of tiotropium in Belgium. The subsuets analysis by no of exacerbations and hospitalisations is very informative and reflects the large heterogeneity in cost-effectiveness for medication in a representative group of patients with COPD. One minor point for improvement would be to give a little more detail on the clinical characteristics of this group, e.g. the distribution over GOLD stages.

Level of interest: An article of outstanding merit and interest in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests